Bioage Labs Inc Revenue Growth Rates (BIOA), Current and Historic Growth - CSIMarket
CSIMarket
 


Bioage Labs Inc   (NASDAQ: BIOA)
 

BIOA's Revenue Growth by Quarter and Year

Bioage Labs Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BIOA/growth
https://api.csimarket.com/api/v1/companies/BIOA/fundamentals
https://api.csimarket.com/api/v1/companies/BIOA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
BIOA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.30
2nd Quarter June 2.45
1st Quarter March 2.77
FY 5.52

BIOAs Annual Revenue
Bioage Labs Inc 's Revenue in the fiscal year 2025 $ 9.00 millions
Bioage Labs Inc 's Revenue in the fiscal year 2024 $ 0.00 millions
Bioage Labs Inc 's Revenue in the fiscal year 2017 $ 14.94 millions
Bioage Labs Inc 's Revenue in the fiscal year 2016 $ 8.27 millions
Bioage Labs Inc 's Revenue in the fiscal year 2015 $ 2.17 millions




BIOA Revenue third quarter 2026 Y/Y Growth Comment
Bioage Labs Inc reported drop in Revenue in the third quarter 2026 by -85.46% to $ 0.30 millions, from the same quarter in 2025.
The fall in the third quarter 2026 Bioage Labs Inc 's Revenue compares unfavorably to the Company's average Revenue jump of 84.63%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 72 other companies have achieved higher Revenue growth. While Bioage Labs Inc ' s Revenue meltdown of -85.46% ranks overall at the positon no. 1130 in the third quarter 2026.




BIOA Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -85.46 %
2nd Quarter June 1.66 %
1st Quarter March 91.03 %
FY   -

Financial Statements
Bioage Labs Inc 's third quarter 2026 Revenue $ 0.30 millions BIOA's Income Statement
Bioage Labs Inc 's third quarter 2025 Revenue $ 2.05 millions Quarterly BIOA's Income Statement


BIOA Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -87.84 %
2nd Quarter June -11.55 %
1st Quarter March -10.06 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #210
Overall #1130

Revenue Y/Y Growth Statistics
High Average Low
539.16 % 84.63 % -45.24 %
(Sep 30 2016)   (Sep 30 2014)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #73
Healthcare Sector #210
Overall #1130
Revenue Y/Y Growth Statistics
High Average Low
539.16 % 84.63 % -45.24 %
(Sep 30 2016)   (Sep 30 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Bioage Labs Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
236.28 % 33.11 % -82.75 %
(Mar 31 2017)  


BIOA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Bioage Labs Inc disclosed fall in Revenue from the second quarter by -87.84% to $ 0.30 millions, from $ 2.45 millions achived in the previous reporting period.

But that's not important problem, as Bioage Labs Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 131 other companies have achieved higher Revenue quarter on quarter growth. While Bioage Labs Inc 's Revenue growth quarter on quarter, overall rank is 2956.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #383
Overall #2956
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #132
Healthcare Sector #383
Overall #2956
Revenue Q/Q Growth Statistics
High Average Low
236.28 % 33.11 % -82.75 %
(Mar 31 2017)  


BIOA's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Bioage Labs Inc disclosed fall in Revenue from the second quarter by -87.84% to $ 0.30 millions, from $ 2.45 millions achived in the previous reporting period.

But that's not important problem, as Bioage Labs Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 131 other companies have achieved higher Revenue quarter on quarter growth. While Bioage Labs Inc 's Revenue growth quarter on quarter, overall rank is 2956.


Bioage Labs Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 10.36
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) 0.38 %
Seq. Revenue Growth (TTM) Overall Ranking # 1135


Cumulative Revenue growth Comment


Bioage Labs Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 211
S&P 500 # 1135
Cumulative Revenue growth Comment


Bioage Labs Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 211
S&P 500 # 1135




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BIOA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Sutro Biopharma Inc -6.14%$ -6.138 millions
Zai Lab Limited-6.79%$ -6.794 millions


About Bioage Labs Inc Revenue Growth Rates (BIOA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.